CLINICAL_TRIALS trial_result · 2024-04-16

Clinical Trial Update: A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors [Phase 2]

Phase 2 trial of KN046 in thymic carcinoma patients who failed prior immune checkpoint inhibitors has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Weill Medical College of Cornell University | Conditions: Thymic Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2024-04-16